Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs PXL 770 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms STAMP-NAFLD
- Sponsors Poxel
- 26 Jun 2021 Results presented at The International Liver Congress 2021.
- 25 Jun 2021 According to a Poxel media release, results from this trial were presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2021.
- 25 Jun 2021 Results published in the Poxel Media Release